Peter Pekos
Direttore/Membro del Consiglio presso CARDIOL THERAPEUTICS INC.
Patrimonio netto: 859 814 $ in data 30/04/2024
Posizioni attive di Peter Pekos
Società | Posizione | Inizio | Fine |
---|---|---|---|
CARDIOL THERAPEUTICS INC. | Direttore/Membro del Consiglio | 15/12/2017 | - |
Independent Dir/Board Member | 15/12/2017 | - | |
Dalton Chemical Laboratories, Inc.
Dalton Chemical Laboratories, Inc. Chemicals: Major DiversifiedProcess Industries Dalton Chemical Laboratories, Inc. engages in the provision of integrated drug discovery, development and manufacturing services. Its products include building blocks, glitazones, labelled compounds, natural compounds, peptides, steroids and controlled drugs. The firm also offers formulation development, flow chemistry, conjugation and contract research services. The company was founded by Peter Pekos in 1986 and is headquartered in Toronto, Canada. | Amministratore Delegato | 01/01/1986 | - |
Fondatore | 01/01/1986 | - | |
Presidente | 01/01/1986 | - | |
Biotechnology Focus | Corporate Officer/Principal | - | - |
Diamond Therapeutics, Inc.
Diamond Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Diamond Therapeutics, Inc. is a Canadian clinical-stage drug development company founded in 2018 by Judy Blumstock. The company is based in an undisclosed location and is focused on developing safe, FDA, EMA, and Health Canada approved therapies for neuropsychiatric conditions. The company is developing sub-perceptual, non-hallucinogenic, psychedelic-based treatments that hold potential for use across a broad patient cohort, with the goal of maximizing the positive impact better drugs can have on the mental health crisis. Diamond's mission is to develop new and better therapies for mental health conditions by unlocking the promise of psychedelic compounds. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Peter Pekos
Precedenti posizioni note di Peter Pekos
Società | Posizione | Inizio | Fine |
---|---|---|---|
Venturelab
Venturelab Miscellaneous Commercial ServicesCommercial Services ventureLAB provides business development solutions. Its programs focuses on capital, talent, technology, and customers. The company is headquartered in Markham, Canada. | Presidente | 01/01/2011 | 01/01/2020 |
Jupiter Consumer Products Ltd. | Fondatore | - | - |
Ashbury Biologicals, Inc. | Fondatore | - | - |
Formazione di Peter Pekos
University of Toronto | Undergraduate Degree |
York University | Graduate Degree |
Statistiche
Distribuzione geografica
Canada | 10 |
Posizioni
Founder | 3 |
Director/Board Member | 2 |
Chief Executive Officer | 1 |
Settori
Consumer Services | 3 |
Health Technology | 3 |
Process Industries | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
CARDIOL THERAPEUTICS INC. | Health Technology |
Aziende private | 6 |
---|---|
Dalton Chemical Laboratories, Inc.
Dalton Chemical Laboratories, Inc. Chemicals: Major DiversifiedProcess Industries Dalton Chemical Laboratories, Inc. engages in the provision of integrated drug discovery, development and manufacturing services. Its products include building blocks, glitazones, labelled compounds, natural compounds, peptides, steroids and controlled drugs. The firm also offers formulation development, flow chemistry, conjugation and contract research services. The company was founded by Peter Pekos in 1986 and is headquartered in Toronto, Canada. | Process Industries |
Ashbury Biologicals, Inc. | |
Jupiter Consumer Products Ltd. | |
Biotechnology Focus | |
Venturelab
Venturelab Miscellaneous Commercial ServicesCommercial Services ventureLAB provides business development solutions. Its programs focuses on capital, talent, technology, and customers. The company is headquartered in Markham, Canada. | Commercial Services |
Diamond Therapeutics, Inc.
Diamond Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Diamond Therapeutics, Inc. is a Canadian clinical-stage drug development company founded in 2018 by Judy Blumstock. The company is based in an undisclosed location and is focused on developing safe, FDA, EMA, and Health Canada approved therapies for neuropsychiatric conditions. The company is developing sub-perceptual, non-hallucinogenic, psychedelic-based treatments that hold potential for use across a broad patient cohort, with the goal of maximizing the positive impact better drugs can have on the mental health crisis. Diamond's mission is to develop new and better therapies for mental health conditions by unlocking the promise of psychedelic compounds. | Health Technology |
- Borsa valori
- Insiders
- Peter Pekos
- Esperienza